Mr. Cohen is a seasoned medical device and pharmaceutical executive with a series of positions leading organizations with full P&L responsibility, and previous departmental management experience in virtually all functional areas, including international sales, R&D, healthcare services, M&A, corporate marketing, legal affairs and business & technology development, coupled with strategic oversight and planning positions. He most recently built significant shareholder value as President & CEO of Travanti Pharma Inc. through technology, product and business development, followed by the successful sale of the company to a larger entity five years after his arrival. Mr. Cohen has held senior management positions with both large organizations (Pfizer Inc.; Sulzermedica; St. Jude Medical) and small enterprises (Travanti Pharma; Advanced Circulatory Systems; Horizon Medical Products; GCI Medical). Diverse activities have included successfully taking a company public on the NYSE, initiating and developing new products through to market, establishing a manufacturing facility in a foreign tax-friendly environment, a series of acquisitions, divestitures and licensing transactions ranging from several thousand dollars to almost one billion dollars, raising capital for early stage companies, and restructuring sales activities in Japan. Mr. Cohen is able to leverage more than thirty years of clinical, distribution, executive, venture capital and investment banking relationships on behalf of Miromatrix.
Mr. Eibensteiner has been President of Wyncrest Capital, Inc. since 1993, an investment company for early-stage technology companies in the area of telecommunications, medical devices and software. Currently, Mr. Eibensteiner is co-founder and Chairman of Software Management Services, Inc., a software supplier to the gaming industry. Additionally, Mr. Eibensteiner co-founded ReadyCredit Corporation in 2005 and served as its Chief Executive Officer and Chairman during its formation and currently serves on the Board. His past investment activities included: co-founder of Diametrics Medical, Inc., a manufacturer of blood gas diagnostic systems; a principal investor and Board member of OnHealth Network Company, a web-based publisher of health and wellness information which was later merged with WebMD; principal investor and Board member of BigCharts, Inc., a provider of financial internet content until its sale to Dow Jones/MarketWatch.com in June 1999; Chairman of the Board of Prodea Software Corporation, a data-warehousing software company, until its sale to Platinum Technology, Inc.; and principal investor and Board of Director member of Travanti Pharma Inc, a specialty drug delivery firm, until its sale to Teikoku Pharmaceutical in May of 2009. Mr. Eibensteiner also served as a member of the Board of Stellant Software (Nasdaq: STEL) from 1996 until 2001. In 1983, Mr. Eibensteiner co-founded Arden Medical Systems and served as its Chief Financial Officer until its sale to Johnson & Johnson in 1987. From 1999 to 2005 Mr. Eibensteiner served as Chairman of the Republican Party of Minnesota and holds a Bachelor of Science in political science from the University of Minnesota.
Timothy P. Flynn
Mr. Flynn is the retired Chairman of KPMG and held a number of key leadership positions throughout his 32-year tenure. KPMG is a global professional services organization, which has 145,000 professionals operating in 152 countries. Most recently (2007-2011), Flynn was Chairman of KPMG International and Flynn also served as Chairman KPMG LLP (2005-2010), KPMG International’s US and largest member firm. In May 2012 Flynn was elected to the Board of Directors of JPMorgan Chase & Co. where he serves on the Directors Risk Advisory and Public Responsibility Committees. In July 2012, Flynn was elected to the Board of Directors of Walmart where he serves on the Directors Audit Committee. In September 2013, Flynn was elected to the Board of Directors of The Chubb Corporation where he serves on the Audit and Finance Committees. Flynn holds a bachelor’s degree in accounting from The University of St. Thomas, St. Paul, Minnesota, where he is a trustee and Vice Chair of the Trustees Executive Committee. He previously has served as a trustee of the Financial Accounting Standards Board, a member of the World Economic Forum’s International Business Counsel, and a Founding member of The Prince of Wales’ International Integrated Reporting Committee.
Timothy J. Pawlenty
Mr. Pawlenty is president and CEO of Financial Services Roundtable, a Washington, D.C.-based industry advocacy group. He served as Governor of the State of Minnesota for two terms (2003-2011). As Minnesota’s Chief Executive Officer, Mr. Pawlenty represented the interests of 5.2 million citizens and was responsible for a $50 billion biennial budget, 30,000 employees and 30 agencies and departments. His work as governor included business development efforts on behalf of Minnesota’s diverse businesses, including the promotion of international business opportunities through trade missions to nine countries. As governor he was responsible for disaster preparedness and response, appointment of Judges and support of Minnesota’s nationally recognized National Guard troops as Commander-In-Chief. As Chair of the State Board of Investment, Mr. Pawlenty provided oversight of $60 billion in investments. The public policy initiatives he proposed and implemented in education, health care and energy were widely viewed as among the most innovative and impactful in the nation. He received Presidential appointments to serve on the Advisory Council on Historic Preservation (2003-2006) and the National Infrastructure Advisory Committee (2006-2010). He served as Chair of the National Governor’s Association (2007-2008), Chair of the Education Commission of the States (2008-2010), and Chair of the Midwest Governor’s Association (2006-2007.) From 1986 to 2000 Mr. Pawlenty practiced law in the areas of criminal prosecution, civil litigation and appeals. He also served as Vice President of Corporate Development for Wizmo, an early stage technology services company. Mr. Pawlenty currently or previously served as a member of the board of directors of Digital River, Miromatrix Medical, Tiburon, Inmar, Red Prairie, NewTel Europe, LLC and Stratika. Mr. Pawlenty served in the Minnesota House of Representatives (1993-2003) where he was elected Majority Leader by his colleagues (January 1999-January 2003). He received a B.A. from the University of Minnesota, Phi Beta Kappa and Phi Kappa Phi honors, and a J.D. from the University of Minnesota Law School.
Walter L. Sembrowich, Ph.D.
Dr. Sembrowich most recently was a Director, Chairman of the Board and formerly Chief Executive Officer of Travanti Pharma Inc. He co-founded and was an advisor to that company since its inception. From 1995 to 1999, he was President of Aviex Inc., an investment and management firm serving start-up and early stage medical companies. In 1990, Dr. Sembrowich co-founded Diametrics Medical, Inc. (DMED: NASDAQ), a manufacturer of point-of-care blood gas and electrolyte systems, where he served as CEO until 1993 and as Co-Chairman of the Board until 1996. He was a co-founder of Arden Medical Systems, Inc., a manufacturer of doctor’s office chemistry systems, and served as Vice President of Scientific Affairs and Director from 1983-1988. Johnson and Johnson purchased Arden in 1987. From 1994 to 2003 he was a director of St. Jude Medical (STJ: NYSE), a global cardiovascular device company. He is a Director of EMVascular Inc. an early stage cardiovascular technology company, and has served on the boards of directors of Integ, eMed, Opticon Medical Inc., CuraMed Systems, Inc., USCardiovascular and Minnesota Project Innovation. He also has served as a reviewer for the Small Business Innovative Research program sponsored by the National Institutes of Health (N.I.H.). Dr. Sembrowich received a BS from Boston University, MS from Illinois State University, and Ph.D. from Washington State University. He was the recipient of an N.I.H. post-doctoral fellowship. He has numerous patents and publications in the fields of medical technology, applied physiology and drug delivery.